{
    "id": "dbpedia_8013_2",
    "rank": 48,
    "data": {
        "url": "https://www.biohaven.com/",
        "read_more_link": "",
        "language": "en",
        "title": "Clinical-stage Biopharmaceutical Company",
        "top_image": "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/OG_Homepage.jpg",
        "meta_img": "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/OG_Homepage.jpg",
        "images": [
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/Biohaven-Full-Color-rgb_v2.svg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/Biohaven-Full-Color-rgb_v2.svg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/Biohaven-White-rgb-2022SEPT05.svg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/bhvn-listed-nyse.svg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/bhvn-listed-nyse-blue.svg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/bhvn-listed-nyse-blue.svg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/pfizer1.jpg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/pfizer1.jpg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/bristolmyerssquibb.jpg 400w, https://c6a2x5m8.rocketcdn.me/wp-content/uploads/bristolmyerssquibb-367x138.jpg 367w",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/bristolmyerssquibb.jpg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/astrazeneca1.jpg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/astrazeneca1.jpg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/catalent1.jpg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/catalent1.jpg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/yaleuniversityschoolofmedicine.jpg 400w, https://c6a2x5m8.rocketcdn.me/wp-content/uploads/yaleuniversityschoolofmedicine-367x138.jpg 367w",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/yaleuniversityschoolofmedicine.jpg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/uconn1.jpg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/uconn1.jpg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/pfizer1.jpg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/pfizer1.jpg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/bristolmyerssquibb.jpg 400w, https://c6a2x5m8.rocketcdn.me/wp-content/uploads/bristolmyerssquibb-367x138.jpg 367w",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/bristolmyerssquibb.jpg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/astrazeneca1.jpg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/astrazeneca1.jpg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/catalent1.jpg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/catalent1.jpg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/yaleuniversityschoolofmedicine.jpg 400w, https://c6a2x5m8.rocketcdn.me/wp-content/uploads/yaleuniversityschoolofmedicine-367x138.jpg 367w",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/yaleuniversityschoolofmedicine.jpg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/uconn1.jpg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/uconn1.jpg",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/Vlad-Coric.png 572w, https://c6a2x5m8.rocketcdn.me/wp-content/uploads/Vlad-Coric-400x403.png 400w",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/Vlad-Coric.png",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/2022/03/two-hex-icon-overlap.png",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/2022/03/two-hex-icon-overlap.png",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/Vlad-Coric.png 572w, https://c6a2x5m8.rocketcdn.me/wp-content/uploads/Vlad-Coric-400x403.png 400w",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/Vlad-Coric.png",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/2022/03/two-hex-icon-overlap.png",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/2022/03/two-hex-icon-overlap.png",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/2022/03/Our-Team-Logo.png",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/2022/03/Our-Team-Logo.png",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/2022/03/Board-of-Directors-Icon.png",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/2022/03/Board-of-Directors-Icon.png",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/2022/03/Scientific-Advisors-Icon-.png",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/2022/03/Scientific-Advisors-Icon-.png",
            "https://c6a2x5m8.rocketcdn.me/wp-content/uploads/Biohaven-White-rgb-2022SEPT05.svg"
        ],
        "movies": [
            "about:blank",
            "https://player.vimeo.com/video/712104690?dnt=1&app_id=122963"
        ],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2022-01-31T13:22:26+00:00",
        "summary": "",
        "meta_description": "Harnessing the boundless potential of scientific innovation to transform the treatment of neurological and neuropsychiatric diseases.",
        "meta_lang": "en",
        "meta_favicon": "//c6a2x5m8.rocketcdn.me/wp-content/uploads/favicon.png",
        "meta_site_name": "Biohaven, Ltd.",
        "canonical_link": "https://www.biohaven.com/",
        "text": "AT BIOHAVEN, WE KNOW DAYS MATTER!\n\nBiohaven is a uniquely different pharmaceutical company. We are an agile and resilient team of highly skilled professionals who eagerly challenge the status quo to advance novel, life-changing therapies. People are at the center of all we do. The unmet needs of patients inspire us to follow scientific innovation wherever it leads and motivate our resolve for overcoming the obstacles that stand in the way of medical progress. It is all part of the patient-first culture we proudly call the “Biohaven Way.”\n\nYour browser does not support HTML5 video.\n\nPROVEN DELIVERY OF BEST‑IN‑CLASS TREATMENTS\n\nBiohaven has a proven commitment to quickly bringing to market best in class therapies to people in need. Prior to May 2022 when Pfizer acquired the CGRP platform, Biohaven received two FDA approvals and EMA approval of Nurtec® ODT (rimegepant), a novel CGRP receptor antagonist for the treatment of migraine and the first and only therapy that both treats and prevents migraine attacks. Between its launch in 2020 and the acquisition in 2022, Nurtec ODT propelled to the #1 prescribed migraine treatment in its class.\n\nWE ARE SOCIAL\n\nCOMMITMENT TO PATIENTS\n\nFueled by our entrepreneurial structure and a portfolio of product candidates, Biohaven is poised to fill the unmet treatment needs of millions of people around the world living with neurological and neuropsychiatric diseases, including rare disorders. We’ve developed and launched a therapy with blockbuster potential that addresses the needs of millions and we are ready to do it again!\n\nWINNING WITH SCIENCE\n\nAt Biohaven, we are harnessing the boundless potential of scientific innovation to transform the treatment of neurological and neuropsychiatric diseases, including rare disorders, while optimizing our pipeline to explore numerous therapeutic adjacencies. Everything we do is built around a steadfast dedication to creating a better future for the people who count on us.\n\nCREATING SHAREHOLDER VALUE\n\nIn the pursuit of our bold mission, we operate with purpose and urgency to turn breakthrough discoveries into best-in-class therapies for diseases with little or no treatment options. As we blaze new trails built upon our understanding of the needs of people with neurological and neuropsychiatric diseases, including rare disorders, we know days matter. We are committed to remaining opportunistic in our R&D efforts while maintaining our responsibility to investors.\n\nOPTIMIZING VALUE THROUGH COLLABORATION & INNOVATION\n\nBiohaven is continuously striving to evolve our approach to drug discovery and development to help people live healthier lives. To enhance our ability to deliver enduring value, we have combined internal research and development with intellectual property licensed from some of the world’s leading global companies and institutions.\n\nOPTIMIZING VALUE THROUGH COLLABORATION & INNOVATION\n\nBiohaven is continuously striving to evolve our approach to drug discovery and development to help people live healthier lives. To enhance our ability to deliver enduring value, we have combined internal research and development with intellectual property licensed from some of the world’s leading global companies and institutions.\n\nSUCCEEDING TOGETHER\n\n“Biohaven continues to be deeply dedicated to alleviating the burden of neurological and neuropsychiatric diseases. We do this with a commitment to patients first and foremost and by resiliently following the path of scientific innovation. As we set a new course, we continue to bring together the brightest minds to grow Biohaven’s unique culture of teamwork, collaboration, and accountability. There is no ceiling on what we can achieve!”\n\nSUCCEEDING TOGETHER\n\n“Biohaven continues to be deeply dedicated to alleviating the burden of neurological and neuropsychiatric diseases. We do this with a commitment to patients first and foremost and by resiliently following the path of scientific innovation. As we set a new course, we continue to bring together the brightest minds to grow Biohaven’s unique culture of teamwork, collaboration, and accountability. There is no ceiling on what we can achieve!”\n\nLEADING BY EXAMPLE"
    }
}